Close Menu

Becton Dickinson

The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.

According to the Wall Street Journal, Becton Dickinson is investigating reports from nursing homes regarding false positive results from its rapid COVID-19 test.

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

High Demand

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The company missed analyst estimates on the top line and provided guidance for its full fiscal year 2020 revenues to decrease 2.5 to 3.0 percent as reported.

The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

The agency said it recommends that clinical laboratory staff and healthcare providers consider any positive result presumptive from the BD SARS-CoV-2 test.

BD has also granted the offerings' underwriters an option to purchase up to an additional $450 million of common stock and depositary shares.

The firm said it will use the funds for general corporate purposes, which may include investment and acquisitions, working capital, and debt repayment.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.